Levonorgestrel-releasing intrauterine device plus metformin, or megestrol acetate plus metformin for fertility-sparing treatment of atypical endometrial hyperplasia and early endometrial carcinoma: a prospective, randomized, blind-endpoint design trial protocol

BACKGROUND: Endometrial adenocarcinoma (EC) is the fifth most common cancer in women worldwide, standard treatment for EC includes hysterectomy, but it results in the loss of reproductive function. Thus, conservative treatment for these patients is strongly demanded, progestin therapy is widely acce...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Xin, Niu, Jumin, Shi, Cong, Liu, Zhihui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9636609/
https://www.ncbi.nlm.nih.gov/pubmed/36333773
http://dx.doi.org/10.1186/s12978-022-01513-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9636609/
https://www.ncbi.nlm.nih.gov/pubmed/36333773
http://dx.doi.org/10.1186/s12978-022-01513-8

Ejemplares similares